Roslindale, Massachusetts Clinical Trials

A listing of Roslindale, Massachusetts clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 109 clinical trials
Individualized Brain Stimulation to Improve Mobility in Alzheimer's Disease

The objective of this study is to conduct a pilot, randomized sham-controlled trials to determine the feasibility and effects of a 10-session personalized tDCS intervention targeting the left dorsolateral prefrontal cortex on cognitive function, dual task standing and walking, and other metrics of mobility in 24 older adults with mild …

dementia
transcranial direct current stimulation
brain stimulation
cognitive impairment
mild cognitive impairment
Hebrew Rehabilitation Center
 (0.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

neurofibroma
multiple meningiomas
schwartz
nf2 gene
cataract
Children's Hospital Boston (Site 725)
 (4.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +16 other locations
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …

growth factor
cancer
stage iv breast cancer
her2/neu-negative breast cancer
estrogen receptor
Massachusetts General Hospital
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +6 other locations
A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

metastatic malignant solid tumor
solid tumour
ki-ras
solid tumor
kras g12c mutation
Dana Farber Cancer Institute
 (4.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +7 other locations
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: Sacituzumab govitecan (IMMU-132) Pembrolizumab (Keytruda; MK-3475)

anticoagulants
pembrolizumab
cns disease
cancer
hair thinning
Dana Farber Cancer Institute
 (4.7 away) Contact site
  • 8 views
  • 19 Feb, 2024
  • 1 location
Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer

This is a first in human study to assess the safety, tolerability, PK, PD and preliminary efficacy of CC-94676 in men with progressive metastatic castration-resistant prostate cancer.

gonadotropin releasing hormone
androgen suppression
androgens
orchiectomy
cancer
Dana Farber Cancer Institute
 (4.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +5 other locations
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the …

carfilzomib
monoclonal protein
line of therapy
autologous hematopoietic stem cell transplant
lenalidomide
Investigational Site Number 8400003
 (4.4 away) Contact site
  • 0 views
  • 24 Nov, 2025
  • +7 other locations
Test trial v7.2 (May 13) - Test 1 (Acro - Test 1)

Test trial v7.2 (May 13) - Test 1

US-Site 1
 (4.8 away) Contact site
  • 0 views
  • 13 May, 2025
  • +2 other locations
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 intramuscular injections of the Acne mRNA vaccine candidate at up to three dose levels in adult participants aged 18 to 45 years with moderate to severe acne. This trial will consist of a …

Metro Boston Clinical Partners- Site Number : 8400008
 (4.6 away) Contact site
  • 0 views
  • 29 Nov, 2025
  • +30 other locations
Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: Ipatasertib Atezolizumab

anticoagulants
cancer
g-csf
sentinel lymph node biopsy
adjuvant
Dana-Farber Cancer Institute
 (4.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location